---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-052454"
form_type: "8-K"
ticker: "LQDA"
cik: "0001819576"
company_name: "Liquidia Corp"
filed_at: "2025-05-23T23:59:59+00:00"
generated_at: "2026-05-20T15:06:31.029853+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# FDA approves Liquidia's YUTREPIA for PAH and PH-ILD, enabling commercial launch

## Summary
- FDA approved YUTREPIA (treprostinil) inhalation powder for PAH and PH-ILD to improve exercise ability.
- Exclusivity for United Therapeutics' Tyvaso DPI expired May 23, 2025, clearing path for YUTREPIA final approval.
- YUTREPIA uses proprietary PRINT technology for deep-lung delivery; pivotal INSPIRE study showed tolerability.
- Liquidia intends to begin commercialization immediately; ongoing litigation may delay or prevent successful commercialization.
- Company will host a webcast May 27, 2025 at 8:30 a.m. ET to discuss commercial launch preparations.

## SEC filing metadata
- accession: 0001104659-25-052454
- form_type: 8-K
- ticker: LQDA
- cik: 0001819576
- company_name: Liquidia Corp
- filed_at: 2025-05-23T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1819576/000110465925052454/0001104659-25-052454-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1819576/000110465925052454/tm2516078d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-052454
- JSON: https://secwatch.observer/filing/0001104659-25-052454.json
- Plain text: https://secwatch.observer/filing/0001104659-25-052454.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.